SAMSUNG-ELECTRONICS
Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today introduced its next-generation 108-megapixel (Mp) image sensor, Samsung ISOCELL Bright HM1. With a spectrum of light-enhancing technologies spanning from Nonacell and Smart-ISO to real-time HDR, ISOCELL Bright HM1 allows brighter and more detailed 108Mp photographs and crystal-clear 8K videos at 24 frames per second (fps), even under extreme lighting conditions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200212005343/en/
“To capture meaningful moments in our lives, Samsung has been driving innovations in pixel and logic technologies that enable ISOCELL image sensors to take astounding photographs even when lighting conditions aren’t ideal,” said Yongin Park, executive vice president of the sensor business at Samsung Electronics. “By adopting Nonacell and Smart-ISO technologies, the 108Mp ISOCELL Bright HM1 helps take vivid high-resolution pictures across a wide range of lighting environments.”
At a 1/1.33” scale with 108-million 0.8μm pixels, the ISOCELL Bright HM1 features the industry's first state-of-the-art Nonacell technology, which delivers brighter images in low-light settings. In 2017, Samsung introduced Tetracell, a pixel-binning technology with a special two-by-two array that merges four neighboring pixels to work as a single large pixel. Nonacell is an enhanced version of Tetracell with a three-by-three pixel structure. In the HM1, Nonacell merges nine neighboring 0.8μm pixels to mimic a large 2.4μm pixel, more than doubling Tetracell’s light absorption.
As the number of adjoined cells increase, so does color interference, making pixel-binning technologies more challenging, While such difficulties had limited Nonacell to a theory, the HM1 was able to realize the method by adopting Samsung’s ISOCELL Plus technology, which dramatically reduces crosstalk and minimizes optical loss as well as light reflection.
For ultimate results under any lighting condition, the HM1 supplements Nonacell with several other advanced pixel technologies. For example, the HM1’s Smart-ISO technology produces vivid and vibrant images by intelligently selecting the optimal ISO. High ISOs are used in darker settings while low ISOs are better for brighter environments to control light saturation.
In challenging mixed-light environments for photo-taking, the HM1’s real-time HDR technology optimizes exposures, producing more natural looking videos and still photographs. By assigning the most appropriate exposure lengths to each pixel, the HM1 is able to capture scenes in multiple exposures simultaneously, generating HDR images in real-time for both preview and capture modes. For sharper results, the HM1 supports a gyro-based electronic image stabilization (EIS) and Super-PD, an advanced phase detection technology for fast and accurate auto-focus.
The HM1 allows users to preview and capture full shots and close-ups of the subject at up to 3x lossless zoom, preserving the quality of the image. This is made possible by the sensor directly converting the pixels using an embedded hardware IP, rather than having the task delegated to the mobile processor. With 108-million pixels, the sensor is also able to produce images up to 3x zoom at a 12Mp resolution without upscaling.
Samsung ISOCELL Bright HM1 is currently in mass production.
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com .
# # #
* Samsung first announced its ISOCELL technology in 2013, which reduces color crosstalk between pixels by placing a physical barrier, allowing small-sized pixels to achieve higher color fidelity. Based on this technology, Samsung introduced the industry’s first 1.0um-pixel image sensor in 2015 and a 0.9-pixel sensor in 2017. In June 2018, Samsung introduced an upgraded pixel isolation technology, the ISOCELL Plus.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200212005343/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
